Tech Company Financing Transactions
Mnemosyne Pharmaceuticals Funding Round
Mnemosyne Pharmaceuticals closed a $5.4 million Series A investment round on 2/17/2012. Investors included Access BridgeGap Ventures and Slater Technology Fund.
Transaction Overview
Company Name
Announced On
2/17/2012
Transaction Type
Venture Equity
Amount
$5,400,000
Round
Series A
Investors
Access BridgeGap Ventures (Lead Investor)
Proceeds Purpose
The company said that it will use the new funds in support of its drug discovery programs, including the identification of lead product candidates for treatment of schizophrenia and other neuropsychiatric disorders.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Technology Sq. 10th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Vanessa King
Chief Scientific Officer
Tim Piser
Vice President
Robert Volkmann
VP - Operations
David Anderson
Browse more venture capital transactions:
Prev: 2/17/2012: Vital Therapies venture capital transaction
Next: 2/17/2012: QuickPay venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs